Alexion Pharmaceuticals Inc. (ALXN) Downgraded by Vetr Inc. to "Strong Sell"


They currently have a $107.00 price objective on the biopharmaceutical company's stock. Vetr 's price target points to a potential downside of 11.86% from the company's previous close.



from Biotech News